Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [1]. Core Views - The report highlights strong performance in new growth markets, achieving annual profitability for the first time [1][3]. - The company reported a revenue of 2.04 billion yuan for the first half of 2024, representing a year-on-year growth of 48% [3]. - The adjusted net profit for the same period was 50 million yuan, with an adjusted net profit margin of 2.5%, an increase of 3.8 percentage points year-on-year [3]. - The report anticipates continued growth in store openings and sales, with a target of 240 new stores in 2024 and 300-350 stores in 2025-2026 [3]. Summary by Relevant Sections Financial Performance - Revenue for 1H24 was 2.04 billion yuan, up 48% year-on-year, with a gross margin of 72.7%, an increase of 0.3 percentage points [3]. - Adjusted EBITDA reached 230 million yuan, a year-on-year increase of 84%, with an EBITDA margin of 11.4%, up 2.2 percentage points [3]. - The company has maintained a strong same-store sales growth for 28 consecutive quarters, with a same-store revenue growth of 3.6% in 1H24 [3]. Store Expansion and Market Strategy - As of June 30, the total number of stores reached 914, with a net addition of 146 stores in 1H24 [3]. - The company has expanded into four new cities and plans to continue its aggressive expansion strategy [3]. - Membership growth has been significant, with a total of 19.4 million members, contributing 63.6% to revenue, an increase of 5.1 percentage points year-on-year [3]. Profitability and Cost Management - The report indicates a clear operating leverage effect, with a notable increase in profitability [3]. - The company’s adjusted net profit for 2024 is projected to be 110 million yuan, reflecting a year-on-year growth of 1203% [5]. - The report also provides updated revenue forecasts for 2024-2026, with expected revenues of 4.21 billion yuan in 2024, 5.28 billion yuan in 2025, and 6.76 billion yuan in 2026 [5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 60 [2][4]. Core Insights - The company's revenue for 1H24 reached RMB 39.5 billion, representing a year-on-year increase of 46.3% and a quarter-on-quarter increase of 12.8%. Product revenue specifically was RMB 38.1 billion, up 55.1% year-on-year and 16.5% quarter-on-quarter, aligning with previous announcements [3]. - The adjusted non-IFRS net loss for 1H24 was RMB 1.6 billion, a reduction of 15.9% year-on-year and 50.6% quarter-on-quarter, which was better than both the report's and market's expectations [3]. - The strong growth in product revenue is attributed to the robust performance of Tyvyt and three biosimilars, as well as the successful launch of new products like Sapitinib and Huiranzhuo [3]. - The company aims for EBITDA breakeven by 2025 and projects a revenue target of RMB 20 billion by 2027, with an expected revenue growth of approximately 30% in the second half of 2024 [3]. Financial Performance Summary - For 2022, the company reported revenue of RMB 4.56 billion, which increased to RMB 6.21 billion in 2023, and is projected to reach RMB 8.58 billion in 2024, reflecting a year-on-year growth of 36.2% [7]. - The adjusted net loss is expected to narrow from RMB 515 million in 2023 to RMB 328 million in 2024, with a return to profitability projected in 2025 with a net profit of RMB 1.7 billion [7]. - The gross margin is expected to improve to 83.0% by 2024, up from 81.7% in 2023 [9]. Research and Development Pipeline - The company is advancing its R&D pipeline, with key updates expected at upcoming conferences regarding IBI363 and other assets [3]. - The management has indicated that the sales efficiency of the oncology pipeline will improve, leading to a decrease in sales and administrative expenses in the second half of 2024 and beyond [3].

社会服务/酒店餐饮 公 司 研 究 特海国际（09658.HK） 2024 年 09 月 01 日 翻台显著增长，换帅后期待开店和多品牌拓展加速 ——公司信息更新报告 投资评级：买入（维持） | --- | --- | |---------------------------|---------------------------| | | | | 初敏（分析师） | 李睿娴（联系人） | | chumin@kysec.cn | liruixian@kysec.cn | | 证书编号： S0790522080008 | 证书编号： S0790122120005 | 开 源 证 券 证 券 研 究 报 告 公司信息更新报告 | --- | --- | |-------------------------|--------------| | 日期 | 2024/8/30 | | 当前股价 ( 港元 ) | 12.660 | | 一年最高最低 ( 港元 ) | 18.260/7.950 | | 总市值 ( 亿港元 ) | 82.33 | | 流通市值 ( 亿港元 ) | 82.33 | | 总股本 ( 亿股 ) | ...

Investment Rating - The report maintains a "Buy" rating for 康方生物 (9926.HK) with a target price of 63 HKD, indicating a potential upside of 28% from the current price of 49.1 HKD [2][3]. Core Insights - The company's 1H24 performance is largely in line with market expectations, achieving revenue of 1.02 billion RMB, with product revenue of 939 million RMB, reflecting a year-on-year growth of 24% [2][3]. - The report highlights the upcoming WCLC conference, where interim analysis data for the K drug head-to-head study in lung cancer is expected to be announced, serving as a key catalyst for the company's stock [2][3]. - The company has initiated seven new Phase III clinical trials in the first half of 2024, focusing on its core assets, 卡度尼利 and 依沃西, with a projected total R&D expenditure of 1.3 to 1.4 billion RMB for the year [2][3]. Financial Performance Summary - For 1H24, 康方生物 reported a gross margin of 91.3%, with a net loss attributable to shareholders of 239 million RMB, compared to a net profit of 253 million RMB in 1H23 [2][3]. - The company’s cash and cash equivalents stood at 5.69 billion RMB as of the end of the first half of 2024 [2][3]. - Revenue projections for the upcoming years are as follows: 2024E at 2.39 billion RMB, 2025E at 3.45 billion RMB, and 2026E at 5.41 billion RMB, with significant year-on-year growth anticipated [3][4]. Clinical Development and Upcoming Catalysts - The report outlines several key data readouts expected in the second half of 2024, including interim analysis data for 依沃西 in the AK112-303 trial and data for 卡度尼利 in the 1L CC trial [2][3]. - The company is also preparing for potential inclusion in the 2024 medical insurance negotiations, which could significantly boost the sales volume of its drugs [2][3]. Valuation and Financial Estimates - The report adjusts the net loss estimates for 2024E to 540 million RMB, with slight adjustments to future profit estimates for 2025E and 2026E [2][3]. - The valuation is based on a DCF model with a WACC of 9.4% and a perpetual growth rate of 3% [2][3].

海吉亚医疗 (06078.HK) 证券研究报告 业绩简评 2024 年 8 月 30 日，公司发布 24 年中期业绩公告。公司 1H24 实现 收入 23.8 亿元（同比+35%），经营利润 5.1 亿元（同比+22%），经 调整净利润 4.0 亿元（同比+16%）。 经营分析 医院业务高速增长，诊疗能力持续提升。截至 2024H1 公司医院业 务收入 23.1 亿元（同比+37%），其中肿瘤业务收入 10.5 亿元（同 比+31%），非肿瘤业务收入 13.4 亿元（同比+39%），整体医院业务 收入保持稳健增长。此外公司提供手术等复杂诊疗服务的能力进 一步提高，2024H1 公司完成手术 46095 例（同比+29%），三四级手 术及介入收入占比稳步提升，手术收入同比增长 38.6%。 自建+并购持续推进，床位数进一步增加。截至 2024H1，公司管理 或经营 16 家以肿瘤科为核心的医院，其中三级医院 4 家，二级医 院 12 家，另外有 2 家再见的三级规模医院，覆盖中国 8 个省份的 13 个城市，终端覆盖逐步完善。此外，公司以并购+自建的方式不 断扩大其医疗服务网络及业务规模。在建医院进展方面，目前 ...

证券研究报告 港股公司|公司点评|名创优品（09896） 国内同店稳健，直营拓店加速 请务必阅读报告末页的重要声明 glzqdatemark1 2024年09月01日 证券研究报告 |报告要点 公司发布 2024Q2 及 2024H1 财务业绩。2024Q2 公司实现收入 40.4 亿元/同比+24.1%，其 中 MINISO 中国/MINISO 海外/TOPTOY 收入同比分别+18.3%/+35.5%/+24.3%。2024Q2 公 司毛利率为 43.9%，创下历史新高；经调净利润为 6.3 亿元/同比+9.4%，若剔除净汇兑损益， 经调净利润同比增长 24.6%。 |分析师及联系人 邓文慧 曹晶 SAC：S0590522060001 SAC：S0590523080001 请务必阅读报告末页的重要声明 1 / 5 名创优品(09896) 国内同店稳健，直营拓店加速 | --- | --- | |----------------------------|---------------------------------| | | | | 行 业： 投资评级： | 商贸零售/专业连锁Ⅱ 增持（维持） | | ...

Investment Rating - The report maintains a "Buy" rating for Anta Sports (02020) with a target price set at 76.80 HKD [1][4]. Core Insights - The company's H1 2024 financial results exceeded expectations, with revenue reaching 33.74 billion HKD, a year-on-year increase of 13.8%. The net profit attributable to shareholders was 7.72 billion HKD, up 62.6% year-on-year. Excluding one-time gains from the listing of Amer Sports, the adjusted net profit was 6.16 billion HKD, reflecting a 17.0% increase [1][4]. - Anta Sports announced a share buyback plan of up to 10 billion HKD over the next 18 months, demonstrating confidence in future growth and commitment to shareholder returns [1][4]. Summary by Sections Financial Performance - H1 2024 revenue was 33.74 billion HKD, up 13.8% year-on-year. The net profit attributable to shareholders was 7.72 billion HKD, a 62.6% increase. Adjusted net profit, excluding one-time gains, was 6.16 billion HKD, reflecting a 17.0% increase [1][4]. - The company declared an interim dividend of 1.18 HKD per share, with a payout ratio of approximately 50% when excluding the one-time gain from Amer Sports [1][4]. Brand Performance - Anta brand revenue for H1 2024 was 16.08 billion HKD, up 13.5%, with a gross margin of 56.6%. FILA brand revenue was 13.06 billion HKD, up 6.8%, with a gross margin of 70.2%. Other brands, including Descente and Kolon, saw revenue growth of over 30% [1][4]. - The online sales channel grew by 25%, increasing its share from 30.8% in H1 2023 to 33.8% in H1 2024. The number of stores for Anta and FILA brands increased, with a focus on the DTC model [1][4]. Inventory and Profitability - Inventory turnover days improved to 114 days, down 10 days year-on-year, contributing to better discount management. The gross margin for H1 2024 was 64.1%, up 0.8 percentage points year-on-year [1][4]. - The net profit margin (excluding Amer Sports) reached a historical high of 18.3%, up 0.5 percentage points year-on-year [1][4]. Future Outlook - The company maintains its revenue growth guidance for the Anta brand at 10%-15% for 2024, while FILA's growth forecast has been adjusted to high single digits. The overall strategy focuses on high-quality growth across multiple brands [1][4].

Investment Rating - Buy/Initiate coverage with a target price of HKD 34.7 [1] Core Views - H1 2024 performance met expectations, with revenue reaching RMB 22.17 billion, up 8.4% YoY, and net profit attributable to shareholders of RMB 6.24 billion, up 8.1% YoY [2] - Green bottle purified water performed well, compensating for the decline in packaged water market share, while sugar-free tea continued to grow rapidly [2] - The company's gross margin decreased by 1.38 percentage points to 58.78% due to increased promotional efforts and lower capacity utilization in the packaged water segment [2] - The company is expected to recover its packaged water market share gradually, with a stable overall operation aiming for high-quality development [2] Product Performance - Packaged water revenue decreased by 18.3% YoY to RMB 8.53 billion, while tea beverage revenue increased by 59.5% YoY to RMB 8.43 billion [2] - Functional beverage revenue grew by 3.8% YoY to RMB 2.55 billion, and juice revenue increased by 25.4% YoY to RMB 2.11 billion [2] - The operating profit margin for packaged water decreased by 4.2 percentage points, while tea beverages saw an increase of 1.0 percentage point [2] Future Outlook - The company expects revenue to grow by 8%, 12%, and 13% in 2024, 2025, and 2026, respectively, reaching RMB 46.21 billion, RMB 51.85 billion, and RMB 58.33 billion [2] - Net profit is projected to grow by 6%, 12%, and 13% over the same period, reaching RMB 12.83 billion, RMB 14.32 billion, and RMB 16.23 billion, respectively [2] - The company's PE ratio is expected to be 19X, 15X, and 13X for 2024, 2025, and 2026, respectively [2] Financial Metrics - The company's net profit margin remained stable at 28.14% in H1 2024, down only 0.08 percentage points YoY [2] - Sales expenses decreased by 0.53 percentage points to 22.42%, while management expenses decreased by 0.56 percentage points to 4.12% [2] - The company's ROE is expected to be 42.28%, 38.93%, 30.28%, and 25.55% for 2023A, 2024E, 2025E, and 2026E, respectively [6]

Investment Rating - The investment rating for the company is "Recommended (Maintain)" with a current stock price of 1.15 HKD [1]. Core Views - The company reported a revenue of 314 million HKD for H1 2024, representing a year-on-year growth of 8.8%, while the net profit attributable to shareholders decreased by 8.1% to 89 million HKD [3]. - The company emphasizes quality improvement and efficiency enhancement in its ongoing projects, with same-store traffic increasing by 16% and same-store sales rising by 8% in H1 2024 [3]. - The overall gross margin stands at 51.6%, with stable margins across most operational models, despite some pressure from new projects still in the cultivation phase [3]. - The company has a strong cash position, with cash increasing by 3.9% compared to the end of 2023, and a dividend payout ratio of 50% [3]. - The company has opened new projects in Guangzhou and Shanghai, continuing its strategic focus on the Greater Bay Area and national expansion [3]. - The associated company, Xinghe Holdings, maintains a stable operation with a AAA credit rating, indicating strong financial health [3]. Financial Summary - For H1 2024, the company achieved a revenue of 314 million HKD, with a gross margin of 51.6% [3]. - The projected earnings per share (EPS) for 2024-2026 are adjusted to 0.15 HKD, 0.16 HKD, and 0.16 HKD respectively, reflecting a decrease from previous estimates [3]. - The price-to-earnings (P/E) ratios for the next three years are projected at 6.9x, 6.7x, and 6.5x [4][3]. - The company’s total assets are projected to grow from 2,325 million HKD in 2023 to 2,984 million HKD by 2026 [7].

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Viewpoints - The company achieved a revenue of 9.1 billion yuan in H1 2024, representing a year-on-year growth of 10.6%, and a net profit attributable to shareholders of 500 million yuan, up 21.5% year-on-year [2]. - The business development is balanced with improved operational efficiency and rapid growth in core profits, supported by employee incentives [2]. - The company has a strong cash reserve of 3 billion yuan and has implemented an employee stock option plan to enhance motivation and productivity [2]. Summary by Relevant Sections Revenue and Profitability - The company reported a revenue of 91 billion yuan in H1 2024, with a gross profit of 17.4 billion yuan, reflecting a gross margin of 19.2%, an increase of 0.5 percentage points year-on-year [2]. - Core operating profit reached 8.9 billion yuan, marking a 25.8% increase year-on-year [2]. Business Segments - Revenue from property management, park services, and consulting services was 60.2 billion yuan, 17.6 billion yuan, and 11.3 billion yuan respectively, with year-on-year growth rates of 14.6%, 6.1%, and 5.3% [2]. - The company manages 3,356 projects with a total managed area of 480 million square meters, providing a solid foundation for future growth [2]. Operational Efficiency - The company has optimized its processes, resulting in a decrease in management expense ratio by 0.6 percentage points, and an overall gross margin increase of 0.5 percentage points to 19.2% [2]. - The gross margins for property management, park services, consulting services, and technology businesses were 14.9%, 23.9%, 32.1%, and 38.7% respectively, with notable improvements in consulting and technology [2]. Financial Outlook - The company forecasts net profits attributable to shareholders of 750 million yuan, 910 million yuan, and 1.08 billion yuan for 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 14, 12, and 10 times [2][3].